Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Rafting Down the Metastatic Cascade: The Role of Lipid Rafts in Cancer Metastasis, Cell Death, and Clinical Outcomes

Joshua D. Greenlee, Tejas Subramanian, Kevin Liu, Michael R. King

Cancer Res (2021) 81 (1): 5–17.

https://doi.org/10.1158/0008-5472.CAN-20-2199

Published: 04 January 2021

View article titled, Rafting Down the Metastatic Cascade: The Role of Lipid Rafts in Cancer Metastasis, Cell Death, and Clinical Outcomes

Journal Articles

Abstract LB-069: TRAILing chemoresistance: Oxaliplatin resistance sensitizes colorectal cancer to TRAIL via death receptor localization

Joshua Dale Greenlee, Nerymar Ortiz-Otero, Tejas Subramanian, Kevin Liu, Michael King

Cancer Res (2020) 80 (16_Supplement): LB-069.

https://doi.org/10.1158/1538-7445.AM2020-LB-069

Published: 15 August 2020

View article titled, Abstract LB-069: TRAILing chemoresistance: Oxaliplatin resistance sensitizes colorectal cancer to TRAIL via death receptor localization

Journal Articles

Abstract 109: Myeloid Syk-PI3Kg-HIF axis inhibits anti-tumor adaptive immunity: In silico design of a “first in class” novel dual-Syk/PI3K inhibitor, SRX3207, to block the immunosuppressive tumor microenvironment

Shweta Joshi, Kevin Liu, Muamera Zulcic, Alok Singh, Timothy Pham, Christopher K. Glass, Andrew Sharabi, Guillermo A. Morales, Joseph R. Garlich, Donald Durden

Cancer Res (2019) 79 (13_Supplement): 109.

https://doi.org/10.1158/1538-7445.AM2019-109

Published: 01 July 2019

View article titled, Abstract 109: Myeloid Syk-PI3Kg-HIF axis inhibits anti-tumor adaptive immunity: <em>In silico</em> design of a “first in class” novel dual-Syk/PI3K inhibitor, SRX3207, to block the immunosuppressive tumor microenvironment

Journal Articles

Abstract 4048: Comprehensive analysis of the suppressed tumor immune microenvironment of CIN gastro-esophageal adenocarcinomas

Sarah Derks, Xinsen Xu, Leonie de Klerk, Tania Fleitas, Kevin Liu, Yang Liu, Claire A. Margolis, Felix Dietlein, Anna Maria Chiaravalli, Annacarolina da Silva, Gordon Freeman, Scott J. Rodig, Eliezer M. Van Allen, Bo Li, Jingxin Fu, Jin Wang, Shirley X. Liu, Adam J. Bass

Cancer Res (2018) 78 (13_Supplement): 4048.

https://doi.org/10.1158/1538-7445.AM2018-4048

Published: 01 July 2018

View article titled, Abstract 4048: Comprehensive analysis of the suppressed tumor immune microenvironment of CIN gastro-esophageal adenocarcinomas

Journal Articles

Abstract 1239: CDKN2B loss promotes progression from benign melanocytic nevus to melanoma

Andrew McNeal, Kevin Liu, Vihang Nakhate, Christopher Natale, Brian Capell, Tzvete Dentchev, Shelley Berger, Meenhard Herlyn, John Seykora, Todd W. Ridky

Cancer Res (2015) 75 (15_Supplement): 1239.

https://doi.org/10.1158/1538-7445.AM2015-1239

Published: 01 August 2015

View article titled, Abstract 1239: CDKN2B loss promotes progression from benign melanocytic nevus to melanoma

Journal Articles

Abstract 4479: Targeting non-small cell lung cancer cells harboring a PIK3CA mutation by a novel and oral PI3K selective inhibitor, PF-4989216

Marlena Walls, Pramod P. Mehta, Sangita M. Baxi, Kevin Liu, Chunze Li, Tod Smeal, Min-Jean Yin

Cancer Res (2011) 71 (8_Supplement): 4479.

https://doi.org/10.1158/1538-7445.AM2011-4479

Published: 15 April 2011

View article titled, Abstract 4479: Targeting non-small cell lung cancer cells harboring a PIK3CA mutation by a novel and oral PI3K selective inhibitor, PF-4989216

Journal Articles

Abstract 5779: The discovery of the potent and selective PI3K/mTOR dual inhibitor PF-04691502 through structure-based drug design

Cancer Res (2010) 70 (8_Supplement): 5779.

https://doi.org/10.1158/1538-7445.AM10-5779

Published: 15 April 2010

View article titled, Abstract 5779: The discovery of the potent and selective PI3K/mTOR dual inhibitor PF-04691502 through structure-based drug design

NARROW

Rafting Down the Metastatic Cascade: The Role of Lipid Rafts in Cancer Metastasis, Cell Death, and Clinical Outcomes

Abstract LB-069: TRAILing chemoresistance: Oxaliplatin resistance sensitizes colorectal cancer to TRAIL via death receptor localization

Abstract 109: Myeloid Syk-PI3Kg-HIF axis inhibits anti-tumor adaptive immunity: In silico design of a “first in class” novel dual-Syk/PI3K inhibitor, SRX3207, to block the immunosuppressive tumor microenvironment

Abstract 4048: Comprehensive analysis of the suppressed tumor immune microenvironment of CIN gastro-esophageal adenocarcinomas

Abstract 1239: CDKN2B loss promotes progression from benign melanocytic nevus to melanoma

Abstract 4479: Targeting non-small cell lung cancer cells harboring a PIK3CA mutation by a novel and oral PI3K selective inhibitor, PF-4989216

Abstract 5779: The discovery of the potent and selective PI3K/mTOR dual inhibitor PF-04691502 through structure-based drug design

Email alerts

AACR Journals

Rafting Down the Metastatic Cascade: The Role of Lipid Rafts in Cancer Metastasis, Cell Death, and Clinical Outcomes

Abstract LB-069: TRAILing chemoresistance: Oxaliplatin resistance sensitizes colorectal cancer to TRAIL via death receptor localization

Abstract 109: Myeloid Syk-PI3Kg-HIF axis inhibits anti-tumor adaptive immunity: In silico design of a “first in class” novel dual-Syk/PI3K inhibitor, SRX3207, to block the immunosuppressive tumor microenvironment

Abstract 4048: Comprehensive analysis of the suppressed tumor immune microenvironment of CIN gastro-esophageal adenocarcinomas

Abstract 1239: CDKN2B loss promotes progression from benign melanocytic nevus to melanoma

Abstract 4479: Targeting non-small cell lung cancer cells harboring a PIK3CA mutation by a novel and oral PI3K selective inhibitor, PF-4989216

Abstract 5779: The discovery of the potent and selective PI3K/mTOR dual inhibitor PF-04691502 through structure-based drug design

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only